Yun-Hee Park

Title: **Yun-Hee Park: A Pioneering Innovator in Antibody-Drug Conjugates**

Introduction

Yun-Hee Park, a talented inventor based in Daejeon, South Korea, has made significant contributions to the field of biomedicine through her innovative work. With a total of three patents to her name, she focuses on developing novel therapies, particularly in the realm of antibody-drug conjugates (ADCs) that have the potential to combat cancer.

Latest Patents

Among the most notable patents held by Yun-Hee Park is an “Antibody-drug conjugate comprising antibody against human ROR1 and use for the same.” This invention pertains to new ADCs that target ROR1, which is associated with the over-expression in various diseases, especially cancer. The patent outlines methods for the preparation of these ADCs, as well as their application in the treatment and prevention of illnesses. Furthermore, it provides a comprehensive pharmaceutical composition involving antibodies that bind to ROR1 or its antigen-binding fragments.

Another significant patent is titled “Antibody-active agent conjugates and methods of use.” This invention presents protein-active agent conjugates characterized by an amino acid motif that is recognized by an isoprenoid transferase. In addition to detailing the compositions that contain these conjugates, the patent also specifies methods for delivering the active agent to a target cell, showcasing the therapeutic potential of these innovations.

Career Highlights

Yun-Hee Park has had a distinguished career, having worked with reputable companies in the biotechnology sector, including Legochem Biosciences, Inc. and Abl Bio Inc. Her experience in these organizations has played a crucial role in the development of her inventive concepts, particularly in the field of drug development and delivery systems.

Collaborations

Throughout her career, Yun-Hee Park has collaborated with notable colleagues, including Yongzu Kim and Taekyo Park. Together, they have focused on advancing research and innovations that contribute to better therapeutic options for patients suffering from challenging health conditions, particularly cancer.

Conclusion

Yun-Hee Park's innovative spirit and commitment to advancing biomedical research through her patents and collaborations are commendable. With her focus on antibody-drug conjugates, she continues to pave the way for new treatment modalities in the battle against cancer and other diseases, demonstrating the vital role of inventors in improving healthcare outcomes.